Literature DB >> 2507135

Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.

J A Ajani1, D M Ota, V B Grossie, B Levin, K Nishioka.   

Abstract

Polyamine biosynthesis is important for cell proliferation and growth. The purpose of this study was to determine the biochemical and pharmacological parameters associated with host toxicity from a continuous infusion of alpha-difluoromethylornithine (DFMO). Twenty-five patients with metastatic carcinoma of the colon or rectum received continuous infusion of DFMO at a median dose of 8 g/m2/day (range, 6-14) for 28 days. DFMO plasma levels, RBC, plasma putrescine, spermidine, and spermine levels, and patient toxicities were evaluated. There was a significant decrease in RBC and plasma levels of putrescine, spermidine, and spermine following DFMO administration compared with the baseline RBC and plasma levels. Pearson correlation coefficient comparing nadir platelet count and steady-state DFMO level was statistically significant (n = 37; P less than 0.01; r = -0.53). Sustained suppression of circulating polyamine levels was also achieved with continuous DFMO infusion. The correlation between steady-state plasma DFMO levels and lowering of platelet count warrants prospective evaluation to determine its clinical usefulness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507135

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Authors:  J A Ajani; D M Ota; V B Grossie; J L Abbruzzese; J S Faintuch; Y Z Patt; D E Jackson; B Levin; K Nishioka
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.

Authors:  V B Grossie; D M Ota; J A Ajani; K Nishioka
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.